Followers | 145 |
Posts | 27575 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Thursday, January 13, 2022 1:14:58 PM
Jan. 13, 2022 11:18 AM ETRedHill Biopharma Ltd. (RDHL)
By: Dulan Lokuwithana, SA News Editor
RedHill Biopharma (NASDAQ:RDHL) announced that its oral COVID-19 therapy opaganib “significantly” improved viral clearance in a Phase 2/3 trial involving severely ill hospitalized patients with the disease.
In patients with positive PCR at screening, the median time to viral RNA clearance with opaganib improved by at least four days. In the opaganib arm, the median for viral clearance was ten days, while the placebo arm did not reach the clearance median by the end of the 14-day treatment.
(Hazard Ratio 1.34; nominal p-value=0.043, N=437/463).
With a median of 11-days from the onset of symptoms, the patient group was much further advanced than the mild-to-moderate outpatients for whom the currently FDA authorized COVID-19 therapies are indicated.
In July, RedHill (RDHL) announced the completion of treatment and follow-up in the 475-patient Phase 2/3 study for opaganib.
Recent RDHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 11:01:56 AM
- RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 • PR Newswire (US) • 05/06/2024 11:00:00 AM
- RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study • PR Newswire (US) • 04/24/2024 11:00:00 AM
- RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights • PR Newswire (US) • 04/08/2024 01:23:00 PM
- RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price • PR Newswire (US) • 04/02/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 11:01:56 AM
- RedHill Announces New USPTO Patent Covering Talicia® Through 2034 • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:01:24 PM
- RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs • PR Newswire (US) • 03/05/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 09:05:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 12:01:50 PM
- RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 01:54:05 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/16/2024 05:15:18 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 09:05:17 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/02/2024 09:10:29 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 03:22:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2024 05:50:54 PM
- RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering • PR Newswire (US) • 01/26/2024 05:46:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2024 02:31:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/26/2024 02:29:37 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 02:09:10 PM
- RedHill Biopharma Announces $8 Million Registered Direct Offering • PR Newswire (US) • 01/25/2024 02:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 11:02:56 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM